MarketCap
Facebook
X
Telegram
Integra LifeSciences Holdings Corporation Income Statement 2025-2007 | IART
Brief overview of financial performance at Integra LifeSciences Holdings Corporation
The conclusions below are based on five years of reported results. Revenue reported by Integra LifeSciences Holdings Corporation was 1.5 billion dollars at the beginning of the period and 1.6 billion dollars at the end. The five-year change reached +6.1%, while CAGR stood at 1.2%. Sales changed only slightly and remained broadly flat.
The five-year change in gross profit reached −7.4%: from $953 million to $882 million. Cost of revenue developed less favorably than sales and pressured gross profitability. At the margin level, the figure shifted from 62.8% to 54.8%. The contraction points to pressure from direct costs or weaker pricing power.
The five-year EBITDA result moved by −61.9%: from 186 million dollars to 70.8 million dollars. EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from 12.2% to 4.4%. The margin contraction indicates weaker operating efficiency.
Comparing the endpoints shows a move from $50.2 million to −$6.9 million. The business lost profitability by the end of the period.
Over the period, capitalization shifted from $4.7 billion to $1.9 billion (−60.2%). The financial trend was stronger than the market valuation.
What the figures show
The current trajectory does not yet confirm a sustainable recovery. The weaker side of the profile includes lower net income, weaker operating efficiency and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Integra LifeSciences Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
945 M | 1.88 B | 3.08 B | 4.67 B | 5.48 B | 5.59 B | 4.73 B | 3.92 B | 4.14 B | 3.07 B | 2.27 B | 1.82 B | 1.32 B | 1.18 B | 796 M | 512 M | 350 M | 524 M | - |
Shares |
76.7 M | 77 M | 80.1 M | 83 M | 84.7 M | 84.6 M | 85.9 M | 84.4 M | 78.4 M | 74.7 M | 73.9 M | 65.5 M | 56.8 M | 55.9 M | 53.7 M | 29.5 M | 29 M | 27.8 M | - |
Historical Prices |
12.3 | 24.4 | 38.5 | 56.3 | 64.7 | 66 | 55 | 47.4 | 52.7 | 41.7 | 30.7 | 27.9 | 23.2 | 21.1 | 14.8 | 17.3 | 12.1 | 18.9 | 23.2 |
Net Income |
-517 M | -6.9 M | 67.7 M | 181 M | 169 M | 134 M | 50.2 M | 60.8 M | 64.7 M | 74.6 M | -3.52 M | 34 M | -17 M | 41.2 M | 28 M | 65.7 M | 51 M | 27.7 M | - |
Revenue |
1.64 B | 1.61 B | 1.54 B | 1.56 B | 1.54 B | 1.37 B | 1.52 B | 1.47 B | 1.19 B | 992 M | 883 M | 928 M | 836 M | 831 M | 780 M | - | - | - | - |
Cost of Revenue |
804 M | 728 M | 657 M | 587 M | 598 M | 521 M | 565 M | 571 M | 436 M | 349 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 953 M | 901 M | 753 M | 643 M | 556 M | 576 M | 502 M | 516 M | 481 M | 123 M | - | - | - |
Operating Income |
-493 M | 28.4 M | 112 M | 239 M | 197 M | 151 M | 93.8 M | 111 M | 44.8 M | 115 M | 79.6 M | 67.9 M | 35.4 M | 73.8 M | 54.9 M | 98.7 M | 97.8 M | 47.4 M | - |
Interest Expense |
-2.35 M | 3.94 M | 51.4 M | 49.6 M | 50.4 M | 71.6 M | 54 M | 64.7 M | 35 M | 25.8 M | 23.5 M | 22 M | 19.7 M | 22.2 M | 27.6 M | 18.4 M | 23.2 M | 30.1 M | - |
EBITDA |
-449 M | 70.8 M | 152 M | 279 M | 237 M | 193 M | 186 M | 132 M | 65.2 M | 129 M | 89.5 M | 77.9 M | 55.8 M | 92.3 M | 71.3 M | 138 M | 138 M | 78.1 M | - |
Operating Expenses |
- | - | - | - | - | - | 794 M | 790 M | 708 M | 528 M | 477 M | 510 M | 459 M | 443 M | 426 M | - | - | - | - |
General and Administrative Expenses |
700 M | 717 M | 657 M | 616 M | 637 M | 595 M | 688 M | 691 M | 624 M | 456 M | 416 M | 446 M | 394 M | 373 M | 358 M | 305 M | 281 M | 281 M | - |
All numbers in USD currency
Quarterly Income Statement Integra LifeSciences Holdings Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
77.3 M | 77 M | 76.8 M | 76.7 M | 76.5 M | 76.4 M | 77.4 M | 77.7 M | 79.7 M | 81 M | 81.9 M | - | 83 M | 83.2 M | 83.6 M | - | 84.8 M | 84.7 M | 84.5 M | - | 84.3 M | 84.7 M | 85.2 M | - | 85.7 M | 85.6 M | 85.3 M | - | 85.2 M | 82.4 M | 78.6 M | - | 78.2 M | 76.2 M | 74.8 M | - | 74.5 M | 74.4 M | 73.9 M | - | 35.3 M | 33 M | 32.7 M | - | 32.4 M | 32.4 M | 32.3 M | - | 27.9 M | 27.9 M | 27.8 M | - | 28.4 M | 28.4 M | 28.3 M | - | 28.6 M | 29.6 M | 29.6 M | 29.6 M | 29.9 M |
Net Income |
4.48 M | -4.62 M | -5.4 M | -484 M | -25.3 M | -10.7 M | -12.4 M | -3.28 M | 19.5 M | 4.18 M | 24.2 M | - | 49.9 M | 44.8 M | 32.9 M | - | 43.2 M | 35.1 M | 45.4 M | 92.7 M | 32.3 M | -369 K | 9.18 M | 15.3 M | -27.6 M | 29.7 M | 32.8 M | 25.1 M | 13.3 M | 11.4 M | 11 M | 44.4 M | 3.16 M | 10.8 M | 6.39 M | 28.2 M | 20.1 M | 12.8 M | 13.4 M | 15 M | -31.9 M | 5 M | 8.38 M | 17.2 M | 9.81 M | 4.82 M | 2.21 M | 13.8 M | -30.3 M | 1.52 M | -6.03 M | 12.8 M | 13.2 M | 8.51 M | 6.69 M | 4.56 M | 11.2 M | 699 K | 11.5 M | 16.5 M | 15.2 M |
Revenue |
419 M | 392 M | 402 M | 416 M | 383 M | 381 M | 418 M | 369 M | 382 M | 381 M | 381 M | - | 385 M | 398 M | 377 M | - | 387 M | 390 M | 360 M | 389 M | 370 M | 259 M | 354 M | 395 M | 379 M | 384 M | 360 M | 383 M | 366 M | 366 M | 357 M | 369 M | 279 M | 282 M | 259 M | - | 250 M | 249 M | 237 M | - | 226 M | 213 M | 203 M | - | 198 M | 231 M | 215 M | - | 213 M | 206 M | 197 M | - | 210 M | - | - | - | - | - | - | - | - |
Cost of Revenue |
199 M | 175 M | 195 M | 206 M | 188 M | 181 M | 192 M | 162 M | 164 M | 174 M | 148 M | - | 148 M | 148 M | 143 M | - | 144 M | 151 M | 146 M | - | 135 M | 105 M | 133 M | - | 143 M | 144 M | 129 M | - | 143 M | 138 M | 144 M | - | 102 M | 99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 242 M | 235 M | 153 M | 221 M | 246 M | 236 M | 240 M | 231 M | 237 M | 223 M | 229 M | 213 M | 220 M | 177 M | 183 M | 172 M | 170 M | 161 M | 160 M | 152 M | 151 M | 140 M | 137 M | 127 M | 134 M | 124 M | 124 M | 113 M | 137 M | 131 M | 124 M | 117 M | 133 M | 131 M | 132 M | 122 M | 121 M | 124 M | 120 M | 116 M | - | - |
Operating Income |
19.3 M | 11.5 M | 11.8 M | -513 M | -15.5 M | -8.15 M | -3.03 M | 3.96 M | 26.6 M | 12.5 M | 36.4 M | - | 65 M | 59.9 M | 46.2 M | - | 56.4 M | 51.9 M | 30.7 M | - | 57.5 M | 14.1 M | 27.1 M | - | -20.6 M | 46 M | 32.3 M | - | 23.7 M | 27.6 M | 25.6 M | - | 10.6 M | 17 M | 9.96 M | - | 30.1 M | 22.4 M | 22.1 M | - | 9.99 M | 24.3 M | 21.2 M | - | 17.1 M | 12.4 M | 8.74 M | - | -31.1 M | 5.56 M | -2.19 M | - | 19.7 M | 18 M | 17.5 M | - | 18.3 M | 8 M | 20.9 M | 27.3 M | 24.6 M |
Interest Expense |
4.19 M | 4.48 M | -842 K | -1.95 M | -144 K | 2.11 M | 1.44 M | -610 K | 471 K | -155 K | 12.1 M | - | 12.8 M | 12.2 M | 11.7 M | - | 12.2 M | 13.1 M | 12.9 M | - | 20.8 M | 15.7 M | 17.8 M | - | 14 M | 13.4 M | 13.1 M | - | 14.5 M | 17.5 M | 18.8 M | - | 6.76 M | 6.18 M | 5.13 M | - | 6.3 M | 6.59 M | 6.37 M | - | 6.46 M | 5.48 M | 5.47 M | - | 5.91 M | 5.38 M | 5.14 M | - | 5.32 M | 4.96 M | 4.8 M | - | 5.55 M | 7.1 M | 7.93 M | - | 7.59 M | 6.72 M | 5.47 M | 4.39 M | 4.3 M |
EBITDA |
23.1 M | 15.2 M | 15.5 M | -509 M | -11.8 M | -4.39 M | 678 K | 14.1 M | 29.8 M | 15.5 M | 39.5 M | - | 68.2 M | 63.2 M | 50.1 M | - | 60.6 M | 56.1 M | 35.2 M | - | 65.9 M | 22.2 M | 56.3 M | - | -15.5 M | 99.9 M | 59.4 M | - | 107 M | 81.6 M | 52.7 M | - | 72.9 M | 58.3 M | 29.7 M | - | 84.4 M | 58.6 M | 40.4 M | - | 50.6 M | 48.7 M | 33 M | - | 51.1 M | 41.6 M | 22.7 M | - | 4.55 M | 29.6 M | 9.2 M | - | 58.9 M | 43.8 M | 30 M | - | 55.6 M | 32.5 M | 30.8 M | 56 M | 43.5 M |
General and Administrative Expenses |
172 M | 178 M | 169 M | 180 M | 181 M | 177 M | 195 M | 166 M | 162 M | 165 M | 167 M | - | 144 M | 161 M | 160 M | - | 156 M | 163 M | 157 M | - | 150 M | 116 M | 166 M | - | 173 M | 165 M | 175 M | - | 173 M | 177 M | 164 M | - | 146 M | 145 M | 142 M | - | 112 M | 119 M | 112 M | - | 113 M | 99.3 M | 93.3 M | - | 93.8 M | 115 M | 108 M | - | 99.8 M | 103 M | 103 M | - | 93.1 M | 96.1 M | 87.4 M | - | 87.5 M | 95.7 M | 80.1 M | 75.7 M | 74.2 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Integra LifeSciences Holdings Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
France
China
Israel
Britain
Canada
